Advanced Oncotherapey Plc Beaufort Securities View

Advanced Oncotherapy Plc (LON:AVO) 
The developer of next-generation proton therapy systems for cancer treatment, yesterday announced that in September 2016, it commenced discussions concerning a proposal it had received from a potential strategic partner that involves, inter alia, non-dilutive financing arrangements. Discussions with this potential partner are continuing and their scope has been expanded. The Group will keep the market informed of any developments accordingly.

Our view: This is good news. Investors are aware that investment spending on LIGHT, as it moves toward final finalisation and demonstration of its first prototype, is burning perhaps £1.3m/month. Last October’s £14m (gross) subscription and open offer raise is rapidly disappearing, which suggests the balance sheet will find itself stretched again by Q3’2017, exactly the time when it could be disastrous for management to take their foot off the ‘development pedal’. Wishing not to suffered a further hit from deeply discounted equity placing which, in any case, would likely just encourage short-termers to flip holdings back and again undermine shares that have recently badly hurt over the past six months, AVO’s Board have sought an alternative solution. It did not see fit to identify the ‘potential strategic partner’ but there must be a strong likelihood that it is Thales Group, the giant French global technology leader for the Aerospace, Transport, Defence and Security markets that last year entered a manufacturing agreement with AVO. With 62,000 employees in 56 countries, having reported 2015 sales of €14 billion, Thales is an enviable partner; yet without irrevocable, binding agreements that formally lock the two enterprises together, both find themselves highly exposed. In the respect that Thales is creating series production lines, has trained up to 160 staff and even registered its own production IP for the manufacture of the LIGHT system, the agreement’s termination would be both severely embarrassing and gather accusations of lost opportunity for such a high-brow enterprise; for AVO it could put the Group’s ability to meet initial market demand back as much as two years and potentially even threaten its ability to continue operations. In a professional sense, the two Group’s need to limit such exposure at the earliest opportunity and, realistically, this is what yesterday’s announcement was all about. If true, the potential ramifications are significant; Thales could possibly agree to move their current manufacturing agreement, with all the cost burdens that AVO would need to shoulder before actually production commences, instead into a formal joint venture. This presumably would entail all such costs being borne by Thales in exchange for long-term exclusivity and a profit sharing arrangement. It would also underline the fact that Thales is both confident that LIGHT will be successfully demonstrated and will create a profit opportunity big enough to interest a business of its scale. On the other hand, such a deep cooperation, must mean that there could only ever be one single bidder for ownership of AVO’s technology, so those waiting for an eventual, highly rewarding, take-out battle to be fought amongst first generation proton bean suppliers stand to be disappointed. Whatever, such a funding solution has to be better than its alternatives for AVO shareholders and Beaufort for one still firmly believes that the commercial opportunity for the LIGHT system remains far from recognised by the markets. Beaufort has the firm belief that news over the coming months will confirm the true value of its technologies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Advanced Oncotherapy Plc

    More articles like this

    Hardman & Co

    Advanced Oncotherapy: Understanding the significance of 230MeV

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology, developed originally at the world-renowned CERN. The complex assembly of the first LIGHT accelerator in Daresbury

    Hardman & Co

    Advanced Oncotherapy: Major milestone achieved

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology, developed originally at the world-renowned CERN. The complex assembly of its first LIGHT accelerator in Daresbury

    Hardman & Co

    Advanced Oncotherapy: LIGHT – regulatory update

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. The company is in the process of completing the complex

    Hardman & Co

    Advanced Oncotherapy: On the home straight

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy: Funded to completion

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy: Leveraging the modularity of LIGHT

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy funded through to clinical events

    AVO’s goal is to deliver an affordable and novel proton therapy (PT) system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, the project has been significantly de-risked

    Hardman & Co

    Advanced Oncotherapy Rapidly changing to commercial execution

    Advanced Oncotherapy plc (LON:AVO) is the topic of discussion when Dr Martin Hall Analyst at Hardman & Co joins DirectorsTalk. Martin talks us through the interesting developments being made at the company, commercial deals, brings us up

    Hardman & Co

    Advanced Oncotherapy Confidence in LIGHT gaining momentum

    The Advanced Oncotherapy PLC (LON:AVO) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has

    Hardman & Co

    Why is Advanced Oncotherapy well positioned for the future?

    Advanced Oncotherapy plc (LON:AVO) is the topic of conversation when Dr Martin Hall, Head of Life Sciences at Hardman & Co joins DirectorsTalk. Martin talks us through some interesting developments at the company, explains what has

    Hardman & Co

    Advanced Oncotherapy FLASH benefits from new US reimbursement

    Advanced Oncotherapy‘s (LON:ONC) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has been de-risked